Testosterone Therapy Labels And Limits May Change Under FDA Proposal

The U.S. Food and Drug Administration, known as the FDA, is proposing changes to the warning labels on testosterone replacement therapy. This is a treatment that gives men extra testosterone when their bodies do not make enough of it. The FDA announced the proposal on June 23, 2026, saying that new scientific studies support updating the rules around who can use the therapy and what risks it carries.

The U.S. Department of Health and Human Services, or HHS, made the announcement on the FDA's behalf. Officials say the current labels are based on older research and no longer reflect what scientists know today. Three main changes are being proposed to bring the labels up to date.

The first change involves men with age-related low testosterone, a condition sometimes called hypogonadism. Since 2015, the label has said that the therapy's safety and effectiveness had not been proven for these men. That warning was added because some doctors worried the treatment might raise the risk of heart problems. However, a large study called the TRAVERSE trial followed more than 5,200 men and found no meaningful increase in serious heart events, like heart attacks or strokes, among those taking testosterone. Because of this new evidence, the FDA says the old warning is no longer needed.

The second change is about prostate cancer. Right now, the label says testosterone therapy should not be used by any man who has or may have prostate cancer. It also warns that the therapy might raise the risk of getting the disease. Under the new proposal, the therapy would only be off-limits for men whose prostate cancer has spread to other parts of the body, which doctors call metastatic cancer. Studies have generally not shown a higher rate of prostate cancer in men using the therapy, but officials note that some uncertainty still remains.

Because prostate cancer can take many years to develop, some studies may not have followed patients long enough to be sure. The revised label would still tell doctors to check patients for cancer before starting treatment and to keep monitoring them while they are on it. This means the update is careful, not careless.

The third change is about an enlarged prostate, a condition called benign prostatic hyperplasia. Current labels warn that testosterone therapy might make symptoms of an enlarged prostate worse. After reviewing the evidence, the FDA found that men with mild to moderate symptoms did not get worse while on the therapy. The updated label would still recommend that doctors closely watch men who have severe symptoms, since the evidence for that group is less clear.

Dr. Michael Davis, acting director of the FDA's Center for Drug Evaluation and Research, explained the importance of keeping labels current. He said these updates give patients and doctors clearer information about the benefits and risks of the therapy. Dr. Brian Christine of HHS added that prescribing information should always reflect the best available science as understanding of a treatment grows over time. The proposed changes have not yet taken effect, as the public and drug companies will have a chance to respond before anything is finalized.